Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of down's syndrome

Experimental Neurology

Volumn 161, Issue 2, 2000, Pages 647-663

  Granholm, Ann Charlotte E ^a   Sanders, Linda A ^a   Crnic, Linda S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Acetylcholine; Basal forebrain; Memory and learning; Nerve growth factor receptors; Neurodegeneration

Indexed keywords

NERVE GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CHOLINERGIC NERVE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; FOREBRAIN; LEARNING DISORDER; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPATIAL MEMORY; TASK PERFORMANCE;

EID: 0034097607     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7289     Document Type: Article

References (70)

1. Antonarakis S. E. 10 years of genomics, chromosome 21, and Down syndrome. Genomics. 51:1998;1-16.
2. Boissiere F., Hunot S., Faucheux B., Hersch L. B., Agid Y., Hirsch E. C. Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer's disease. Dementia Geriatric Cog. Disord. 8:1997;1-8.
3. Boissiere F., Faucheux B., Ruberg M., Agid Y., Hirsch E. C. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Exp. Neurol. 145:1997;245-252.
4. Bäckman C., Rose G. M., Hoffer B. J., Henry M. A., Bartus R. T., Friden P., Granholm A-Ch. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J. Neurosci. 16:1996;5437-5442.
5. Casanova M. F., Walker L. C., Whitehouse P. J., Price D. L. Abnormalities of the nucleus basalis in Down's syndrome. Ann. Neurol. 18:1985;310-313.
6. Charles V., Mufson E. J., Friden P. M., Bartus R. T., Kordower J. H. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res. 728:1996;193-203.
7. 125I) nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience. 62: 1994;625-629.
8. Corsi P., Coyle T. Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse. Proc. Natl. Acad. Sci. USA. 88: 1991;1793-1797.
9. Coyle J. T., Singer H., McKinney M., Price D. Neurotransmitter specific alterations in dementing disorders: Insights from animal models. J. Psych. Res. 18: 1984;501-512.
10. Coyle J. T., Oster-Granite M. L., Gearhart J. D. The neurobiologic consequences of Down's syndrome. Brain Res. Bull. 16: 1986;773-787.
11. Coyle J. T., Oster-Granite M. L., Reeves R. H., Gearhart J. D. Down syndrome, Alzheimer's disease and the trisomy 16 mouse. TINS. 11: 1988;390-394.
12. Crnic L. S., Pennington B. F. Down syndrome: Neuropsychology and animal models. Prog. Infancy Res. 1:1999;69-111.
13. Davisson M. T., Schmidt C., Akeson E. C. Segmental trisomy of murine chromosome 16: A new model system for studying Down syndrome. Prog. Clin. Biol. Res. 360: 1990;263-280.
14. Davisson M. T., Schmidt C., Akeson E. C. Segmental trisomy as a mouse model for Down's syndrome. Prog. Clin. Biol. Res. 348: 1993;117-133.
15. Davisson M. T., Costa A. Mouse models of Down syndrome. Popko B. Mouse Models of Human Genetic Neurological Disease. 1999;297-327 Plenum, New York.
16. Denenberg V. H., Sherman G. F., Schrott L. M., Rosen G. D., Galaburda A. M. Spatial learning, discrimination learning, paw preference and neocortical ectopias in two autoimmune strains of mice. Brain Res. 562:1991;98-104.
17. Detoledo-Morrell L., Sullivan M. P., Morrell F., Wilson R. S., Bennett D. A., Spencer S. Alzheimer's disease: In vivo detection of differential vulnerability of brain regions. Neurobiol. Aging. 18:1997;463-468.
18. Diaz-Brinton R., Yamazaki R. S. Advances and challenges in the prevention and treatment of Alzheimer's disease. Pharmaceut. Res. 15:1998;386-398.
19. Ebadi M., Bashir R. M., Heidrick M. L., Hamada F. M., Refaey H. E., Hamed A., Helal G., Baxi M. D., Cerutis D. R., Lassi N. K. Neurotrophins and their receptors in nerve injury and repair. Neurochem. Int. 30:1997;347-374.
20. Ehlers M. D., Kaplan D. R., Price D. L., Koliatsos V. E. NGF-stimulated tramsport of trkA in the mammalian nervous sytem. J. Cell Biol. 130: 1995;149-156.
21. Emmett C. J., Aswani S. P., Stewart G. R., Fairchild D., Johnson R. M. Dose-response comparison of recombinant human nerve growth factor and recombinant human basic fibroblast growth factor in the fimbria fornix model of acute cholinergic degeneration. Brain Res. 673:1995;199-207.
22. Escorihuela R. M., Fernandez-Teruel A., Vallina I. F., Baamonde C., Lumbreras M. A., Dierssen M., Tobena A., Florez J. A behavioral assessment of Ts65Dn mice: A putative Down syndrome model. Neurosci. Lett. 199:1995;143-146.
23. Fahnestock M., Scott S. A., Jette N., Weingartner J. A., Crutcher K. A. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res. 42:1996;175-178.
24. Fiedler J. L., Epstein C. J., Rapoport S. I., Caviedes R., Caviedes P. Regional alteration of cholinergic function in central nervous system of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). Brain Res. 658:1994;27-32.
25. Fisher W, Wictorin K., Björklund A., Williams L. R., Varon S., Gage F. H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by NGF. Nature (Lond.). 329: 1987;53-61.
26. Fischer W., Björklund A., Chen K., Gage F. H. NGF improves spatial memory in aged rodents as a function of age. J. Neurosci. 11: 1991;1889-1906.
27. Gellerman L. W. Chance orders of alternating stimuli in visual discrimination experiments. J. Gen. Psychol. 42:1933;206-208.
28. Gnahn H., Hefti F., Heumann R., Schwab M. E., H, Thoenen. NGF-mediated increase of choline acetyl-transferase (ChAT) in the neonatal rat forebrain: Evidence for a physiological role of NGF in the brain? Dev. Brain Res. 9:1983;45-52.
29. Greenberg B. D., Murphy M. F. Toward an integrated discovery and development program in Alzheimer's disease: The amyloid hypothesis. Neurobiol. Aging. 15:1994;105-109.
30. Hefti F., Will B. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons: Implications for Alzheimer's disease? J. Neural Transm. 24:1987;309-315.
31. Hefti F., Schneider L. S. Nerve growth factor and Alzheimer's disease. Clin. Neuropharm. 14:1991;S62-S76.
32. Hock C., Heese K., Muller-Spahn F., Hulette C., Rosenberg C., Otten U. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci. Lett. 241:1998;151-154.
33. Holtzman D. M., Li Y., Chen K., Gage F. H., Epstein C. J., Mobley W. C. Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration. Neurology. 43:1993;2668-2673.
34. Holtzman D. M., Kilbridge J., Chen K. S., Rabin J., Luche R., Carlson E. J., Epstein C. J., Mobley W. C. Preliminary characterization of the central nervous system in partial trisomy 16 mice. Epstein C. J., Hassold T., Lott I. T., Nadel L., Patterson D. Etiology and Pathogenesis of Down Syndrome. 1995;227-240 Wiley, New York.
35. Holtzman D. M., Santucci D., Kilbridge J., Chuacouzens J., Fontana D. J., Daniels S. E., Johnson R. M., Chen K., Sun Y. L., Carlson E., Alleva E., Epstein C. J., Mobley W. C. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. USA. 93:1996;13333-13338.
36. Insausti A. M., Megias M., Crespo D., Cruz-Orive A. M., Dierssen M., Vallina T. F., Insausti R., Florez J. Hippocampal volume and neuronal number in Ts65Dn mice: A murine model of Down syndrome. Neurosci. Lett. 253:1998;175-178.
37. Jette N., Cole M. S., Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res. Mol. Brain Res. 25:1994;242-250.
38. Kish S., Karlinsky H., Becker L., Gilbert J., Rebbetoy M., Chang L. J., DiStefano L., Hornykiewicz O. Down syndrome patients begin life with normal levels of brain cholinergic markers. J. Neurochem. 52:1989;1183-1187.
39. Koliatsos V. E., Clatterbuck R. E., Nauta H. J. W., Knusel B., Burton L. E., Hefti F. F., Mobley W. C., Price D. L. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann. Neurol. 30:1991;831-840.
40. Koliatsos V. E. Biological therapies for Alzheimer's disease: Focus on trophic factors. Crit. Rev. Neurobiol. 10:1996;205-238.
41. Markowska A. L., Koliatsos V. E., Breckler S. J., Price D. L., Olton D. S. Human nerve growth factor improves spatial memory in aged but not in young rats. J. Neurosci. 14: 1994;4815-4824.
42. Markowska A. L., Price D. L., V. E, Koliatsos. Selective effects of nerve growth factor on spatial recent memory is assessed by a delayed nonmatching-to-position task in the water maze. J. Neurosci. 16:1996;3541-3548.
43. Megias M., Verduga R., Dierssen M., Florez J., Insausti R., Crespo D. Cholinergic, serotonergic, and catecholaminergic neurons are not affected in Ts65Dn mice. NeuroReport. 8:1997;3475-3478.
44. Milward E. A., Papadopoulos R., Fuller S. J., Moir R. D., Small D., Beyreuther K., Masters C. L. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 9:1992;129-137.
45. Mufson E. J., Conner J. M., Kordower J. H. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis. NeuroReport. 6:1995;1063-1066.
46. Mufson E. J., Li J. M., Sobreviela T., Kordower J. H. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. NeuroReport. 8:1996;25-29.
47. Mufson E. J., Lavine N., Jaffar S., Kordower J. H., Quirion R., Saragovi H. U. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp. Neurol. 146:1997;91-103.
48. Murase K., Nabeshima T., Robitaille Y., Quirion R., Ogawa M., Hayashi K. NGF level is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem. Biophys. Res. Commun. 193:1993;198-203.
49. Narisawa-Saito M., Wakabayashi K., Tsuji S., Takahashi H., Nawa H. Regional specificity of alterations in NGF, BDNF, and NT-3 levels in Alzheimer's disease. NeuroReport. 7:1996;2925-2928.
50. Nelson P. G., Fitzgerald S., Rapoport S. I., Neale E. A., Galdzicki Z Z., Dunlap V., Bowers L., v Agoston D. Cerebral cortical astroglia from the trisomy 16 mouse, a model for down syndrome, produce neuronal cholinergic deficits in cell culture. Proc. Natl. Acad. Sci. USA. 94:1997;12644-12648.
51. Perry E. K., Tomlinson B. E., Blessed G., Perry R. H., Cross A. J., Crow T. J. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2:1978;1457-1459.
52. Pittler S. J., Baehr W. Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse. Proc. Natl. Acad. Sci. USA. 88:1991;8322-8326.
53. Polani P. E., Adinolfi M. Chromosome 21 of man, 22 of great apes, and 16 of the mouse. Dev. Med. Child Neurol. 22:1980;223-225.
54. Reeves R. H., Irving N. G., Moran T. H., Wohn Q., Kitt C., Sisodia S. S., Schmidt C., Bronson R. T., Davisson M. T. A mouse model for Down syndrome exhibits learning and behavioral deficits. Nature Genet. 11:1995;177-184.
55. Sago H., Carlson E. J., Smith D. J., Kilbridge J., Rubin E. M., Mobley W. C., Epstein C. J., Huang T. T. Ts108Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. USA. 95:1998;6256-6261.
56. Salehi A., Verhaagen J., Dijkhuisen P. A., Swaab D. F. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience. 75:1996;373-387.
57. Scali C., Casamenti F., Pazzagli M., Bartollini L., Pepeu G. Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci. Lett. 170: 1994;117-120.
58. Scott S. A., Mufson E. J., Weingartner J. A., Skau K. A., Crutcher K. A. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15:1995;6213-6221.
59. Seiler M., Schwab M. E. Specific retrograde transport of nerve growth factor receptor (NGF) from neocortex to nucleus basalis in the rat. Brain Res. 300:1984;33-39.
60. Siarey R. J., Stoll J., Rapoport S. I., Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down's syndrome. Neuropharmacology. 36:1997;1549-1554.
61. Smith D. J., Stevens M. E., Sudanagunta S. P., Bronson R. T., Makhinson M., Watabe A. M., O'Dell T. J., Fung J., Weier H. U. G., Cheng J. F., Rubin E. M. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nature Genet. 16:1997;28-36.
62. Sobreviela T., Clary D. O., Reichardt L. F., Brandabur M. M., Kordower J. H., Mufson E. J. TrkA-immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J. Comp. Neurol. 350:1994;587-611.
63. Strada O., Hirsch E. C., Javoy-Agid F., Lehericy S., Ruberg M., Hauw J. J., Agid Y. Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain. J. Neurosci. 12:1992;4766-4774.
64. Sumarsono S. H., Wilson T. J., Tymms M. J., Venter D. J., Corrick C. M., Kola R., Lahoud M. H., Papas T. S., Seth A., Kola I. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature. 379:1996;534-537.
65. Tuszynski M. H., Roberts J., Senut M. C., Hs U., Gage F. H. Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther. 3:1996;305-314.
66. Van Broeckhoven C. Genes in early onset Alzheimer's disease: Implications for AD research. Neurobiol. Aging. 15:1994;149-153.
67. Williams L. R., Varon S., Peterson G. M., Wictorin K., Fisher W., Björklund A., Gage F. H. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc. Natl. Acad. Sci. USA. 83:1986;9231-9235.
68. Winkler J., Thal L. J., Gage F. H., Fisher L. J. Cholinergic strategies for Alzheimer's disease. J. Mol. Med. 76:1998;555-567.
69. Yaar M., Zhai S., Pilch P. F., Doyle S. M., Eisenhauer P. B., Fine R. E., Gilchrest B. A. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis: Possible mechanism for Alzheimer's disease. J. Clin. Invest. 100:1997;2333-2340.
70. Yates C. M., Simpson J., Gordon A., Maloney J., Allison Y., Ritchie I. M., Urquart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 280: 1983;119-126.